A Phase 2b Study of CITI-002 in Patients with Grade 2 and 3 Haemorrhoids
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Lidocaine/hydrocortisone (Primary)
- Indications Haemorrhoids
- Focus Therapeutic Use
- 25 Sep 2019 According to a Citius Pharmaceuticals media release, the company announced that the proceeds will be used for this trial.
- 13 Mar 2018 New trial record
- 06 Mar 2018 According to a Citius Pharmaceuticals media release, following a Type C meeting with the FDA which included discussion of results of the phase 2a study, the company also requested the Agencys feedback on the phase 2b study design, including target patient population, inclusion/exclusion criteria, and efficacy endpoints.